跳转至内容
Merck
CN

SML0099

醋酸肤轻松

≥98% (HPLC)

别名:

(6α,11β,16α)-21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, Lonide

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C26H32F2O7
化学文摘社编号:
356-12-7
分子量:
494.52
NACRES:
NA.77
PubChem Substance ID:
329825157
UNSPSC Code:
51111800
EC Number:
206-597-6
MDL number:
MFCD00079302

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1

InChI key

WJOHZNCJWYWUJD-IUGZLZTKSA-N

SMILES string

CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]23C

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +75 to +90°, c = 1 in dichloromethane

color

white to tan

solubility

DMSO: ≥19 mg/mL

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

Flucinonide is a fluorinated glucocorticid that is used as a topical anti-inflammatory agent. Recently, flucinonide and other fluorinated glucocorticolids were identified as smoothend agonists. Flucinonide induces expression of Gli-reporter luciferase in Shh-LIGHT2 cells.
Fluocinonide has been used to study its effect on T-cell proliferation.
Fluocinonide is shown to be effective in the treatment of atopic dermatitis and oral lichen planus (OLP).
very potent corticosteroid

signalword

Danger

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

hcodes

H300,H361

Hazard Classifications

Acute Tox. 2 Oral - Repr. 2

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000414874
0000414874
0000135057
0000135058
0000061760

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Emily Hix et al.
Dermatology online journal, 19(10), 20029-20029 (2013-10-22)
Adherence in the treatment of chronic inflammatory skin diseases such as atopic dermatitis is poor. Methods to improve adherence have proven difficult. To determine whether a short course of treatment with a high-potency corticosteroid will improve adherence compared to longer
Małgorzata Radwan-Oczko
Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 22(6), 893-898 (2014-01-17)
Oral lichen planus is a common, chronic mucosal disease associated with a cell-mediated immunological dysfunction. The clinical manifestation is different when various forms, white and red, are considered. Erosive, atrophic, ulcerative lesions require long-term treatment, because of inflammation and severe
N Deslauriers et al.
FEMS immunology and medical microbiology, 11(1), 45-55 (1995-03-01)
Using an experimental model in the mouse we have shown that both local and central lines of defense, involving CD4+ T cells, participate in a dynamic interaction to maintain a long-term carrier state of Candida albicans in the oral cavity.
Localized acral pityriasis lichenoides chronica: report of a case.
Jennifer J Halbesleben et al.
The Journal of dermatology, 38(8), 832-834 (2011-03-01)
Brad A Yentzer et al.
Cutis, 86(4), 208-213 (2010-12-15)
Variations in adherence may cause variations in treatment outcomes with topical corticosteroid therapy for atopic dermatitis. An intensive short course of outpatient treatment may promote good adherence and provide a high level of efficacy. The purpose of this study was
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持